Silexion Therapeutics Corp (SLXN) · Nov 19, 2026 · Delisting
Nasdaq stay granted — $2.5M private placement by December 4; $5M public offering by March 31
Silexion’s Nasdaq listing survives for now, but the company must complete $7.5 million of planned financings and clear a near-term bid-price test.
Silexion is a cash-constrained, clinical-stage biotech advancing SIL204, an RNAi therapy for KRAS-driven cancers, with its Phase 2/3 pancreatic-cancer trial now underway and its first patient dosed in September 2026.
The immediate delisting threat has been pushed back, not eliminated. Nasdaq granted continued listing, which preserves the exchange access Silexion relies on to raise capital, but only under a demanding compliance plan. 〔0〕
The cost of staying listed is substantial new execution risk. Silexion must complete a private placement for $2.5 million of net proceeds by December 4, 2026, maintain a closing bid of at least $1 for ten consecutive trading days by November 24, and complete a public offering of at least $5 million by March 31, 2027. The company had about $4.8 million of cash at September 30, 2026 and reported shareholders’ equity of roughly $3.0 million, so the financing requirement is not simply optional growth capital; it is tied directly to keeping the listing and funding the clinical program.
The reverse split helped address the share-price deficiency, but the Nasdaq decision leaves Silexion on probation. The company must maintain all other listing requirements through May 15, 2027, with immediate delisting if it fails another requirement. 〔1〕
Bottom line: This is a modest business positive because Silexion avoids immediate delisting and keeps access to Nasdaq capital markets. But it is not a clean resolution: the company now has to execute a near-term private placement, a larger follow-on offering, and a bid-price test to preserve that status.⃝
Private placement deadline, December 4, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!